Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases

2009 ◽  
Vol 24 (4) ◽  
pp. 176-182 ◽  
Author(s):  
C M Hamel-Desnos ◽  
J-L Gillet ◽  
P R Desnos ◽  
F A Allaert
Keyword(s):  
Varicose Veins ◽  
Randomized Study ◽  
Factor V Leiden ◽  
Factor V ◽  
Factor V Leiden Mutation ◽  
Vein Thrombosis ◽  
Ultrasound Monitoring ◽  
Thrombotic Complications ◽  
High Level ◽  
Deep Vein

Objectives The aim of this study was to assess thrombotic complications following sclerotherapy in thrombophilic patients in combination with thromboprophylaxis, in two randomized arms using low molecular weight heparin (LMWH) or warfarin. Patients and methods This study received approval from the Ethics Committee. A total of 105 patients (81 females, 24 males) ranging in age from 20 to 82 years (mean 50) were selected: 75 with Factor V Leiden mutation, 18 with prothrombin 20210A mutation, 7 with high level of Factor VIII, 5 combinations of these. After randomization, 51 and 54 patients received warfarin and LMWH, respectively. A total of 199 sclerotherapy sessions were performed. Foam was used in 160 treatments. Results No episodes of symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) occurred; no instances of DVT were revealed by ultrasound-monitoring. Conclusions This study suggests that in the three most common forms of thrombophilia, sclerotherapy, in combination with thromboprophylaxis, can be performed safely. Prophylaxis with LMWH is easier to use than warfarin.

Results of Factor V Leiden Mutation Screening in Patients with Deep Vein Thrombosis

2013 ◽  
Vol 22 (1) ◽  
pp. 110-116 ◽  
Author(s):  
Olcay Murat DİŞLİ ◽  
Barış AKÇA ◽  
Köksal DÖNMEZ ◽  
Cengiz ÇOLAK ◽  
Hasan Berat CİHAN ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Mutation Screening ◽  
Factor V Leiden ◽  
Factor V ◽  
Factor V Leiden Mutation ◽  
Vein Thrombosis ◽  
Deep Vein

Deep Vein Thrombosis during Varicella in a Child with Factor V Leiden Mutation and Familial Deficiency of Protein S

2001 ◽  
Vol 85 (02) ◽  
pp. 370-370
Author(s):  
Luca Masotti ◽  
Giacomo Zanelli ◽  
Stefania Battistini ◽  
Sandro Forconi ◽  
Roberto Cappelli
Keyword(s):  
Deep Vein Thrombosis ◽  
Factor V Leiden ◽  
Protein S ◽  
Factor V ◽  
Factor V Leiden Mutation ◽  
Vein Thrombosis ◽  
Deep Vein

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

The Lancet ◽  
1995 ◽  
Vol 346 (8990) ◽  
pp. 1593-1596 ◽  
Author(s):  
K.W.M. Bloemenkamp ◽  
F.M. Helmerhorst ◽  
F.R. Rosendaal ◽  
J.P. Vandenbroucke ◽  
H.R. Büller
Keyword(s):  
Deep Vein Thrombosis ◽  
Oral Contraceptives ◽  
Factor V Leiden ◽  
Factor V ◽  
Third Generation ◽  
Factor V Leiden Mutation ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals Risk Factor Profiles in Patients with Different Clinical Manifestations of Venous Thromboembolism: A Focus on the Factor V Leiden Mutation

1996 ◽  
Vol 76 (04) ◽  
pp. 510-513 ◽  
Author(s):  
Bert Manten ◽  
Rudi G J Westendorp ◽  
Ted Koster ◽  
Pieter H Reitsma ◽  
Frits R Rosendaal
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Clinical Manifestations ◽  
Factor V Leiden ◽  
Factor V ◽  
Factor V Leiden Mutation ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Deep Vein

Summary Background. Patients with venous thromboembolic disease may present with different clinical manifestations. Factor V Leiden mutation leading to resistance to activated protein C is associated with a sevenfold increased risk for presenting with deep-vein thrombosis. It is not yet established whether carriers of the mutation have a similarly increased risk for manifesting with pulmonary embolism. Methods. From an Anticoagulation Clinic monitoring coumarin therapy, a consecutive series of patients with a first thromboembolic event (objectively proven by current radiological methods) were enrolled. All patients were interviewed and blood was drawn for geno-typing. From the hospital charts and the personal interview, information was obtained on acquired risk factors and the signs and symptoms on hospital admission. Results. 45 patients presented with symptoms of pulmonary embolism only, 211 had only symptoms of deep-vein thrombosis whereas 23 had clinical features of both. In about half of the patients acquired risk factors for venous thromboembolism were present which did not differ between the three groups of patients. Recent surgery had been performed more often in patients presenting with pulmonary embolism than in other patients (33.3% vs. 18.5%, p <0,05). Factor V Leiden was present in 9% of the patients presenting with pulmonary embolism (relative risk: 3.3 95% Cl: 1.0-10.6) and 17% of the patients presenting with deep-vein thrombosis (relative risk: 6.9 95% Cl: 3.6-12.8). The prevalence of factor V Leiden was intermediate in patients with both clinical characteristics. Conclusion. These data suggest that patients with venous thromboembolism have different clinical presentation depending on the risk factor profile. Factor V Leiden may preferentially lead to manifest deep-vein thrombosis. Differences in structure of venous thrombi could underlie differences in embolic tendency.

Factor V Leiden mutation in Egyptian patients with deep vein thrombosis

2016 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
MonaH.A. Yaman ◽  
MohamedM Elwageh ◽  
AmiraY Abd-Elnaby ◽  
ManalA.W. Eid
Keyword(s):  
Deep Vein Thrombosis ◽  
Factor V Leiden ◽  
Factor V ◽  
Factor V Leiden Mutation ◽  
Vein Thrombosis ◽  
Egyptian Patients ◽  
Deep Vein
Sign in / Sign up

Export Citation Format

Share Document